There is one clinical trial.
The primary objective of this study is to establish differences in susceptibility to SARS CoV-2 infection among health care workers (HCW) highly exposed to patients with COVID-19 diagnosis. To ascertain this issue, we evaluated: - Changes in receptor polymorphism (ACE2 and CD26 receptor study. - SARS-CoV-2 CD4/CD8 T cell response (CTL) - Different KIR phenotypes
Description: ACE2 analysisMeasure: Susceptibility to SARS CoV-2 infection according to ACE2 receptor Time: 1 month
Description: Activation of CD4-CD8 by viral peptidesMeasure: Cellular immune response to SARS CoV-2 infection Time: 1 month
Description: Analysis of KIR in NK cellsMeasure: Susceptibility to infections according to KIR phenoytpes Time: 2 months
Description: SurveyMeasure: Characteristics of exposure in time and intensity of HCW with SARS CoV-2 infection Time: 1 month
Description: Activation of CD4-CD8 by viral peptidesMeasure: Cellular immune response in HCW with positive IgG against SARS CoV-2 Time: 1 month
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports